Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics Limited announced the issuance of 46,929,731 fully paid ordinary shares to new and existing investors at an issue price of $0.0185 per share. This move, executed without disclosure under the Corporations Act, aims to strengthen the company’s financial position and support its operations in the competitive global diagnostic market. The announcement confirms Atomo’s compliance with relevant legal provisions and assures stakeholders of its transparency and adherence to regulatory standards.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices enhance usability and reliability for rapid point-of-care (POC) and at-home testing, with products commercialized internationally. Atomo has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.
Average Trading Volume: 458,408
Technical Sentiment Signal: Buy
Current Market Cap: A$12.14M
See more data about AT1 stock on TipRanks’ Stock Analysis page.